Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Keryx Biopharmaceuticals Jumped 27.3% in March

By Brian Feroldi - Apr 7, 2017 at 9:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A series of positive announcements led to big gains in March.

What happened

Keryx Biopharmaceuticals (KERX), a commercial-stage biopharma focused on renal disease, rose more than 27% in March, according to data from S&P Global Market Intelligence.

Businessman fanning $100 bills

Image source: Getty Images.

So what

Keryx reported a number of positive developments during March that captured the market's attention. Here's a review of the highlights:

  • Keryx reported its fourth-quarter results. Total revenue rose 65% to $9.53 million, which is a solid result given that the company was still dealing with supply-disruption issues through November. That figure also squeaked by the $9.5 million in revenue that Wall Street was expecting.
  • Management announced that the largest Medicare Part D plan sponsor in the U.S. has added Keryx's lead product Auryxia to its formulary. The company now believes that 85% of patients with Medicare and commercial insurance plans can access the drug.
  • Keryx also announced that it made good on its promise to file a label-expansion claim for Auryxia with the U.S. Food and Drug Administration. The agency accepted the company's label-expansion application, for the treatment of iron deficiency anemia in patients with non-dialysis-dependent chronic kidney disease. The target date for a decision is Nov. 6, 2017.

Given the upbeat financial, reimbursement, and regulatory news, it is easy to understand why traders bid up shares during the period.

Now what

2017 is shaping up to be a make-or-break year for Keryx. Now that Auryxia's supply issues are firmly in the rearview mirror, the company can put all of its resources into growing sales. That should be an easier task now that payers are on board. Meanwhile, a potential label expansion into the non-dialysis market provides the company with a real shot at massively growing its addressable market. Finally, Keryx still hasn't announced its commercialization plans for Europe; a definitive plan to commercialize the drug in the region could be enough to get the markets excited.

On the downside, Keryx is still losing money hand over fist. Net loss in 2016 was $161 million, which means that the company's current cash balance of $112 million might not be enough to see it through the end of the year. That could hint that another capital raise could be on the way.

Overall, Keryx remains an interesting company that has bet the farm on the success of Auryxia. While the upside could be substantial if everything works out, I'd recommend that potential investors continue to approach this stock with caution.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Keryx Biopharmaceuticals, Inc. Stock Quote
Keryx Biopharmaceuticals, Inc.
KERX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.